DelveInsight’s, “Idiopathic Pulmonary Fibrosis (IPF) – Pipeline Insight, 2020,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
Idiopathic Pulmonary Fibrosis Understanding
Idiopathic Pulmonary Fibrosis: Overview
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that results in scarring (fibrosis) of the lungs for an unknown reason. Over time, the scarring gets worse and it becomes hard to take in a deep breath and the lungs cannot take in enough oxygen. Idiopathic pulmonary fibrosis is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs), and not directly affecting the airways or blood vessels. Some people with idiopathic pulmonary fibrosis develop other serious lung conditions, including lung cancer, blood clots in the lungs (pulmonary emboli), pneumonia, or high blood pressure in the blood vessels that supply the lungs (pulmonary hypertension).
Symptoms
The most common signs and symptoms of idiopathic pulmonary fibrosis are shortness of breath and a persistent dry, hacking cough. Many affected individuals also experience a loss of appetite and gradual weight loss. Some people with idiopathic pulmonary fibrosis develop widened and rounded tips of the fingers and toes (clubbing) resulting from a shortage of oxygen. These features are relatively nonspecific; not everyone with these health problems has idiopathic pulmonary fibrosis. Other respiratory diseases, some of which are less serious, can cause similar signs and symptoms.
Diagnosis
Although no single test can diagnose IPF, your doctor may recommend a number of different tests including:
• Pulmonary function test (PFT), Six-minute walk test:
• Chest x-ray
• Blood tests
• Computed tomography (CT scan)
• Bronchoscopy
• Surgical lung biopsy


Treatment
Treatment options include corticosteroids, immunosuppressive/cytotoxic agents (e.g., azathioprine, cyclophosphamide), and antifibrotic agents (e.g., colchicine or d-penicillamine) alone or in combination. Pirfenidone (Esbriet) and nintedanib have both been shown to slow the progression of IPF; however, some patients cannot take these medications due to their side effects. Some additional medications can be used to improve the symptoms of IPF, such as shortness of breath and cough. This includes treatment of gastroesophageal reflux with anti-acid therapy and treatment of shortness of breath with opioids (a class of medications that includes morphine). Other treatments include supplemental oxygen, pulmonary rehabilitation (exercise training, education and support for people with chronic lung disease), and lung transplant.
Idiopathic Pulmonary Fibrosis Emerging Drugs Chapters
This segment of the Idiopathic Pulmonary Fibrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Idiopathic Pulmonary Fibrosis Emerging Drugs
• Pamrevlumab: FibroGen
Pamrevlumab is a first-in-class antibody that inhibits the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders, characterized by persistent and excessive fibrous tissue which can lead to organ dysfunction and failure, and in cancer, characterized by promotion of tumor growth. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration has granted Orphan Drug Designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD. Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration for the treatment of patients with IPF and LAPC.
• TRK-250/BNC-1021: BONAC Corporation; Toray
TRK-250/BNC-1021 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, a key growth factor involved in lung fibrosis, at the gene expression level. One of the features of the agent is that it is a single strand long-chain nucleic acid with a unique molecular structure employing BONAC’s proprietary nucleic acid platform, and it is expected to be a new nucleic acid medicine that has overcome the issue of stability. Moreover, it is in an aerosol form that can be administered directly to the lung, which is expected to carry the agent efficiently to the target organ.

Further product details are provided in the report……..
Idiopathic Pulmonary Fibrosis: Therapeutic Assessment
This segment of the report provides insights about the different Idiopathic Pulmonary Fibrosis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Idiopathic Pulmonary Fibrosis
There are approx. 10+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, Genfit, Zydus Discovery and others.
Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase II and Phase II/III)
• Mid-stage products (Phase II and Phase II/III)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Proteins and Peptides

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Idiopathic Pulmonary Fibrosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Idiopathic Pulmonary Fibrosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Idiopathic Pulmonary Fibrosis drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Idiopathic Pulmonary Fibrosis R&D. The therapies under development are focused on novel approaches to treat/improve Idiopathic Pulmonary Fibrosis.
• August 2020: Chemomab Ltd., a clinical-stage biotech company focusing on discovery and development of innovative therapeutics for fibrosis-related diseases, announced that the European Commission (EC) has granted Orphan Drug Designation (ODD) to its lead drug candidate CM-101 for the treatment of patients with Primary Sclerosing Cholangitis (PSC), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).
• August 2020: CymaBay Therapeutics, Inc. announced positive topline results from ENHANCE, a placebo-controlled, randomized, Phase 3 study evaluating the safety and efficacy of seladelpar for the treatment of Idiopathic Pulmonary Fibrosis (IPF). Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist that has demonstrated anti-cholestatic and anti-inflammatory effects in clinical studies for PBC.
Idiopathic Pulmonary Fibrosis Report Insights
• Idiopathic Pulmonary Fibrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Idiopathic Pulmonary Fibrosis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Idiopathic Pulmonary Fibrosis drugs?
• How many Idiopathic Pulmonary Fibrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Idiopathic Pulmonary Fibrosis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Idiopathic Pulmonary Fibrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Idiopathic Pulmonary Fibrosis and their status?
• What are the key designations that have been granted to the emerging drugs?
Key Players
• Trevi Therapeutics
• FibroGen
• Toray Industries, Inc.
• Novartis
• Suzhou Zelgen Biopharmaceuticals Co.,Ltd.
• Algernon Pharmaceuticals
• Pliant Therapeutics, Inc.
• Galapagos NV
• Kadmon Corporation, LLC
• Boehringer Ingelheim
• Hoffmann-La Roche

Key Products
• Nalbuphine ER
• Pamrevlumab
• TRK-250
• VAY736
• Jaktinib Dihydrochloride
• TD139
• Ifenprodil
• PLN-74809
• GLPG1690
• KD025
• BIBF 1120